Ascendis Pharma A/S Noncurrent Liabilities
Ascendis Pharma A/S (ASND) had Noncurrent Liabilities of EUR 396.00 million as of 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Notes
ifrs-full:NoncurrentLiabilities · last filed 2026-02-11
- 2025-12-31: Noncurrent Liabilities 396.00M EUR.
- 2025-09-30: Noncurrent Liabilities 342.34M EUR.
- 2025-06-30: Noncurrent Liabilities 340.47M EUR.
- 2025-03-31: Noncurrent Liabilities 365.74M EUR.
| Period end | Noncurrent Liabilities | Noncurrent Liabilities as first filed |
|---|---|---|
| 2025-12-31 | 396.00M EUR 20-F · filed 2026-02-11 | |
| 2025-09-30 | 342.34M EUR 6-K · filed 2025-11-12 | |
| 2025-06-30 | 340.47M EUR 6-K · filed 2025-08-07 | |
| 2025-03-31 | 365.74M EUR 6-K · filed 2025-05-01 | |
| 2024-12-31 | 377.34M EUR 20-F · filed 2026-02-11 | |
| 2024-09-30 | 352.65M EUR 6-K · filed 2024-11-14 | |
| 2024-06-30 | 231.70M EUR 6-K · filed 2024-09-03 | |
| 2024-03-31 | 241.71M EUR 6-K · filed 2024-05-02 | |
| 2023-12-31 | 234.78M EUR 20-F · filed 2025-02-12 | 773.94M EUR 20-F · filed 2024-02-07 |
| 2023-09-30 | 733.89M EUR 6-K · filed 2023-11-07 | |
| 2023-06-30 | 566.71M EUR 6-K · filed 2023-09-05 | |
| 2023-03-31 | 600.71M EUR 6-K · filed 2023-04-27 | |
| 2023-01-01 | 109.61M EUR 20-F · filed 2025-02-12 | |
| 2022-12-31 | 655.12M EUR 20-F · filed 2024-02-07 | |
| 2022-09-30 | 679.03M EUR 6-K · filed 2022-11-02 | |
| 2022-06-30 | 603.86M EUR 6-K · filed 2022-08-10 | |
| 2022-03-31 | 609.08M EUR 6-K · filed 2022-05-11 | |
| 2021-12-31 | 100.93M EUR 20-F · filed 2023-02-16 | |
| 2021-09-30 | 95.55M EUR 6-K · filed 2021-11-10 | |
| 2021-06-30 | 94.06M EUR 6-K · filed 2021-08-27 | |
| 2021-03-31 | 89.57M EUR 6-K · filed 2021-05-27 | |
| 2020-12-31 | 88.28M EUR 20-F · filed 2022-03-02 | |
| 2020-09-30 | 30.11M EUR 6-K · filed 2020-11-12 | |
| 2020-06-30 | 29.09M EUR 6-K · filed 2020-08-27 | |
| 2020-03-31 | 30.76M EUR 6-K · filed 2020-05-19 | |
| 2019-12-31 | 31.63M EUR 20-F · filed 2021-03-10 | |
| 2019-09-30 | 31.50M EUR 6-K · filed 2019-11-18 | |
| 2019-06-30 | 31.46M EUR 6-K · filed 2019-08-28 | |
| 2019-03-31 | 13.21M EUR 6-K · filed 2019-05-30 |